Latent Reservoir for HIV-1 Test and Adjusted Resting Cell Infection: An Important Concern in Present HIV Care

Dear Editor, It is still a major issue in worldwide public health, HIV. It is a crucial issue for basic public health care in all nations. Antiviral drug technology has advanced recently, making it feasible to successfully limit the progression of the disease in an infected instance. It is possible for viral load to decline after effective antiviral medication therapy, and in certain cases, this decline may be seen by using the standard viral load test. Antiretroviral therapy (ART), which is currently being widely used, is unable to completely eradicate it, which impedes the advancement of HIV treatment.[1-4] The main obstacle to curing HIV infection at the moment is the longevity of the latent reservoir of the virus. When HIV infects a person, the latent HIV cannot be detected. In the present day, the new laboratory test for monitoring successful viral load-suppressed HIV-infected cases after antiretroviral drug management is possible. Activating virus transcription and virus generation to cause virus- or immune-mediated cell death is one method for getting rid of latently infected cells that remain in HIV-positive individuals receiving antiretroviral therapy.[2] The term for this is latency reversal.[2] Clinical investigations of latency-reversing medicines have not demonstrated a significant reduction in latently infected cells, despite the obvious action of numerous latency reversal agents in vitro.[2] Measuring the latent reservoir for HIV-1 is a new test that should be discussed. In reservoir tests, near full genome sequencing (nFGS) of individual proviruses is used to assess the proportion of intact proviruses. The majority (9 kb) of the genome is captured by a long-distance outer PCR used in nFGS techniques, which is then followed by nested inner PCRs.[3] Currently, the goal of HIV eradication therapy depends greatly on an accurate quantitation of the latent HIV-1 reservoir. Estimation of the resting CD4(+) T-cell infection reservoir (the overall method is known as resting cell infection, or RCI).[4] An assessment of nFGS methods utilizing the intact proviral DNA assay (IPDA), a multiplex digital droplet PCR assay that quantitates both intact and defective proviruses with single-molecule sensitivity using only short, highly efficient amplicons, was carried out in a recent paper by White et al.[3] It was discovered that nFGS procedures are ineffective and miss roughly 70% of full-length proviruses since the initial outer PCR phase’s amplification stage failed.[3] Crooks et al. noted in the prior article that a 6-fold drop is a suitable threshold to accurately identify the benefits of antilatency therapies on RCI.[4] Based on the documented inaccuracy of the latent reservoir for the HIV-1 test, the authors made a modification to the rate given here. Because only 30% of cases are correctly diagnosed, the modified criterion has been raised to a 20-fold reduction. To avoid underdiagnosing the issue of the latent reservoir for HIV-1, the adjusted rate should be utilized for monitoring antiretroviral therapy. The precise estimation of the latent HIV-1 reservoir is critical for HIV eradication therapy success. The RCI approach, which measures the amount of the resting CD4(+) T-cell infection reservoir, is one way utilized for this assessment. However, White et al. recently assessed the efficacy of next-generation sequencing (nFGS) technologies, notably the IPDA, in estimating the latent reservoir. The study found that nFGS techniques, particularly the initial outer PCR amplification stage, were unsuccessful, missing over 70% of full-length proviruses. This means that quantifying the latent reservoir using present approaches is considerably hampered. Moving forward, it is critical to address the flaws found in the measurement of the latent HIV-1 reservoir. Future research should concentrate on establishing more precise and dependable methods for calculating the size of the latent reservoir. This could include experimenting with new techniques or improving on existing methods for detecting and quantifying full-length proviruses. Efforts should also be directed toward exploring the consequences of the altered criterion of a 20-fold reduction in the context of antiretroviral medication monitoring. Additional research is required to assess the therapeutic importance of this amended criterion and its impact on treatment results. The current study investigates the assessment of the HIV-1 latent reservoir, which is critical for appropriate antiretroviral medication monitoring. The researchers investigated the efficacy of nFGS technologies, specifically the IPDA. The data, however, revealed that nFGS techniques were unsuccessful, missing roughly 70% of full-length proviruses due to a failure in the initial outer PCR amplification stage. The study proposes a change to the threshold for reliably recognizing the advantages of antilatency therapy on resting CD4(+) T-cell infection reservoir (RCI) to solve this issue. Given the confirmed inaccuracy of the latent reservoir test, the original 6-fold reduction criterion is increased to a 20-fold reduction. This modification seeks to avoid underdiagnosing the problem. In the future, several key steps can be taken to advance the field of quantifying the HIV-1 latent reservoir and monitoring antiretroviral therapy. Firstly, there is a need for the development and validation of improved quantification methods that can accurately assess the size of the latent reservoir. Standardizing protocols for quantification and conducting comprehensive validation studies will be crucial in this regard. Secondly, research should focus on understanding the clinical significance of the adjusted 20-fold reduction threshold and its impact on treatment outcomes. Longitudinal studies tracking changes in the latent reservoir over time will provide valuable insights. Additionally, exploring combination approaches and personalized treatment strategies based on biomarkers or genetic signatures associated with the latent reservoir can further enhance therapeutic interventions. Finally, efforts should be made to translate research findings into clinical practice by establishing guidelines and protocols for implementing improved quantification methods in routine care. Finally, reliable quantification of the latent HIV-1 reservoir is critical for HIV eradication therapy. The assessment of nFGS approaches for calculating the latent reservoir found major limitations. To reliably evaluate the impact of antiretroviral medication, an adjusted threshold of a 20-fold reduction should be used. Future studies should concentrate on refining quantification methods and comprehending the consequences of the altered threshold for treatment monitoring. Author contribution Mungmunpuntipantip: Ideas, writing, analyzing, approval; Wiwanitkit: Ideas, supervising, approval Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.